Research programme: serotonin 2a antagonists - Pfizer
Alternative Names: G-protein coupled receptors-cardiovascular therapies research programme - PfizerLatest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arterial thrombosis
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Arterial-thrombosis in USA
- 02 Aug 2005 This programme is still in active development - (BIO-2005)